• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeo Pharma closes upsized $6.6M private placement

April 27, 2021 By Sean Whooley

Valeo PharmaValeo Pharma announced today that it closed an upsized private placement worth more than $6.6 million.

Montreal, Canada-based Valeo issued 6,645 unsecured, non-convertible debenture units at a purchase price of $1,000 per unit, totaling gross proceeds of $6.645 million, according to a news release.

Each debenture unit consists of one unsecured non-convertible debenture in the principal amount of $1,000 and 200 Class “A” share purchase warrants, each of which entitles the holder to purchase one Class “A” share of the company at an exercise price of $1.60 per share at any time up to 24 months following the closing date of the offering.

Debentures will mature, at the latest, nine months after the closing of the offering and bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.

The securities issued under the offering are subject to a four-month hold period. The company has paid $38,500 as finder’s fees to arm’s-length parties in connection with the private placement and issued 7,700 broker warrants. Insiders, senior executives, staff members and three company directors participated, bringing in $2.6 million for the placement.

Proceeds from the offering are expected to be used for working capital and general corporate purposes. Valeo develops prescription products focused on treating respiratory diseases, among other things. Its offerings include the Breezhaler asthma treatments and the Redesca low molecular weight heparin biosimilar.

“The closing of this upsized placement is testament to the confidence and support our insiders and those close to the company have in management and Valeo’s business model,” Valeo CEO Steve Saviuk said in the release. “I cannot overemphasize what a pivotal year 2021 is becoming with the recent launch of Redesca and the imminent launches of Enerzair Breezhaler and Atectura Breezhaler.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory Tagged With: Valeo Pharma

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS